CSL Behring To Present New Real-World Data on Outcomes Following Acute Coronary Syndrome at the American Heart Association (AHA) Virtual Scientific Sessions 2020
KING OF PRUSSIA, Pa., Nov. 10, 2020 /PRNewswire/ -- Global biotherapeutics leader CSL Behring today announced that results of two separate analyses will be shared at this year's American Heart Association (AHA) Scientific Sessions 2020, being held virtually from November 13-17. The data include real-world data from a U.S. Medicare claims database on the clinical and economic impact of major adverse cardiovascular events (MACE) and rehospitalizations in the 90-day, high-risk period following an acute myocardial infarction (MI). CSL Behring will also host a Learning Studio session with Drs. Deepak Bhatt and Peter Libby of Brigham and Women's Hospital to discuss cholesterol efflux, an emerging target area for novel therapies.
"Our research on cardiovascular disease and its impact on public health includes real-world studies on cardiovascular care and our ongoing Phase 3 AEGIS-II trial of CSL112, a novel therapy being investigated to improve outcomes in heart attack survivors," said Larry Deckelbaum, Vice President, Research and Development, Cardiovascular and Metabolic Therapeutic Area at CSL Behring. "We are excited to be a part of the AHA Scientific Sessions and share new findings from this research which include important real-world insights on the 90-day, high-risk period that follows a heart attack."
The presentations at this year's AHA Scientific Sessions include:
Title and Details Presentation Date/Time
---
Abstract: P1708 November 13, 2020, 10:00 a.m. EDT;
also available on demand for
duration of congress
Major Adverse
Cardiovascular
Events and
Hospital
Readmissions in
the 90 Days
Following Acute
Myocardial
Infarction:
Redefining the
Risk Period
---
Abstract: P2318 November 13, 2020, 10:00 a.m. EDT;
also available on demand for
duration of congress
Impact of Race and
Ethnicity on Long
Term Outcomes Post
Percutaneous
Coronary
Intervention With
Drug Eluting
Stents
---
Learning Studio November 15, from 3:45-4:30 p.m.
session: EDT; a recording of the session
will be made digitally available
until Jan 4, 2021
Improving Early
Outcomes for the
Post-AMI Patient:
Cholesterol Efflux
and the Role of
ApoA-I in Plaque
Stabilization
Includes
presentations by specialist, both
Dr. Deepak L. of Brigham and
Bhatt, executive Women's Hospital
director of and Harvard
Interventional Medical School
Cardiovascular
Programs and Dr.
Peter Libby,
cardiovascular
medicine
A live Q&A will
follow.
---
About CSL112
CSL112, Apolipoprotein A-I (Human), is a novel formulation of human plasma-derived apoA-I, the primary functional component of high-density lipoproteins (HDL). Studies have shown that an infusion of CSL112 rapidly enhances cholesterol efflux capacity. Cholesterol efflux is the first and most critical step in reverse cholesterol transport and is the body's primary mechanism for clearing cells of excess cholesterol that would otherwise continue to accumulate in plaque. This build-up of plaque over time can rupture and potentially cause a cardiovascular event. Compared to the standard of care, CSL112 is a therapy that may offer a unique approach to reduce the risk of cardiovascular death, myocardial infarction (MI), and stroke in acute coronary syndrome (ACS) patients diagnosed with either STEMI or NSTEMI.
About cardiovascular disease
Cardiovascular disease is the leading cause of death globally, with an estimated 800,000 acute MIs occurring each year in the U.S. alone.(1,2) Patients who survive a heart attack are at high risk of experiencing early recurrent CV events. The majority of these 1-year recurrent CV events (approximately 60%) occur in the first 90 days after the index event.(3) Although the overall rate of MIs has decreased over the last two to three decades,(4) the proportion of the events occurring in the first 90 days remains unchanged.
About CSL Behring
CSL Behring is a global biotherapeutics leader driven by its promise to save lives. Focused on serving patients' needs by using the latest technologies, the company develops and delivers innovative therapies that are used to treat coagulation disorders, primary immune deficiencies, hereditary angioedema, respiratory disease, and neurological disorders. The company's products are also used in cardiac surgery, burn treatment and to prevent hemolytic disease of the newborn.
CSL Behring operates one of the world's largest plasma collection networks, CSL Plasma. The parent company, CSL Limited (ASX:CSL;USOTC:CSLLY), headquartered in Melbourne, Australia, employs more than 27,000 people worldwide, and delivers its life-saving therapies to people in more than 100 countries. For inspiring stories about the promise of biotechnology, visit Vita at CSLBehring.com/vita and follow us on Twitter.com/CSLBehring.
1. World Health Organization. Cardiovascular diseases (CVDs)- Fact Sheet.
2017.
2. Benjamin E, et al. American Heart Association. Heart Disease and Stroke
Statistics--2018 Update. Circulation. 2018;137:e1-e442.
3. Wallentin L, Becker RC, Budaj A, et al. Ticagrelor versus clopidogrel in
patients with acute coronary syndromes. N Engl J Med.
2009;361(11):1045-1057.
4. Szummer K, et al. Improved outcomes in patients with ST-elevation
myocardial infarction during the last 20 years are related to
implementation of evidence-based treatments: experiences from the
SWEDEHEART registry 1995-2014. Eur Heart J. 2017; 38:3056-3065.
Media Contact:
Natalie de Vane
Mobile: 610-999-8756
Email: Natalie.deVane@cslbehring.com
View original content to download multimedia:http://www.prnewswire.com/news-releases/csl-behring-to-present-new-real-world-data-on-outcomes-following-acute-coronary-syndrome-at-the-american-heart-association-aha-virtual-scientific-sessions-2020-301169181.html
SOURCE CSL Behring
